By Dr Subotheni Thavaneswaran

Journal articles

Thavaneswaran S; Kok PS; Price T, 2017, 'Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis', Expert Review of Anticancer Therapy, 17, pp. 965 - 979, http://dx.doi.org/10.1080/14737140.2017.1369881

Segelov E; Thavaneswaran S; Waring PM; Desai J; Robledo KP; Gebski VJ; Elez E; Nott LM; Karapetis CS; Lunke S; Chantrill LA; Pavlakis N; Khasraw M; Underhill C; Ciardiello F; Jefford M; Wasan H; Haydon A; Price TJ; Van Hazel G; Wilson K; Simes J; Shapiro JD, 2016, 'Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian gastro-intestinal trials group ICECREAM study', Journal of Clinical Oncology, 34, pp. 2258 - 2264, http://dx.doi.org/10.1200/JCO.2015.65.6843

Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N, 2016, 'ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours', BMC Cancer, 16, http://dx.doi.org/10.1186/s12885-016-2389-8

Price T; Thavaneswaran S; Burge M; Segelov E; Haller D; Punt C; Arnold D; Karapetis C; Tebbutt N; Pavlakis N; Gibbs P; Shapiro J, 2016, 'Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015', Expert review of anticancer therapy, 16, pp. 557 - 571, http://dx.doi.org/10.1586/14737140.2016.1170594

Thavaneswaran S; Price TJ, 2016, 'Optimal therapy for resectable rectal cancer', Expert Review of Anticancer Therapy, 16, pp. 285 - 302, http://dx.doi.org/10.1586/14737140.2016.1130627

Thavaneswaran S; Shapiro J; Segelov E, 2016, 'Is there a role for epidermal growth factor receptor inhibition in the treatment of advanced esophagogastric tumours?', Translational Cancer Research, 5, pp. S1214 - S1221, http://dx.doi.org/10.21037/tcr.2016.11.29

Segelov E; Thavaneswaran S; Waring P; Desai J; Mann K; Elez E; Chantrill L; Pavlakis N; Nott L; Underhill C; Khasraw M; Wasan H; Ciardiello F; Jefford M; Joubert W; Haydon A; Karapetis C; Price T; Wilson K; Shapiro J, 2015, 'The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation', European journal of cancer, 51, pp. S726 - S726

Peterson TA; Bielawny T; Lacap P; Hardie R-A; Daniuk C; Mendoza L; Thavaneswaran S; Kariri T; Kimani J; Wachihi C; Kimani M; Ball TB; Plummer FA; Luo M, 2014, 'Diversity and Frequencies of HLA Class I and Class II Genes of an East African Population', Open Journal of Genetics, 2014, pp. 99 - 124, http://dx.doi.org/10.4236/ojgen.2014.42013

Peterson TA; Kimani J; Wachihi C; Bielawny T; Mendoza L; Thavaneswaran S; Narayansingh MJ; Kariri T; Liang B; Ball TB; Ngugi EN; Plummer FA; Luo M, 2013, 'HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort', Tissue Antigens, 81, pp. 93 - 107, http://dx.doi.org/10.1111/tan.12051

Peters HO; Mendoza MG; Capina RE; Luo M; Mao X; Gubbins M; Nagelkerke NJD; MacArthur I; Sheardown BB; Kimani J; Wachihi C; Thavaneswaran S; Plummer FA, 2008, 'An integrative bioinformatic approach for studying escape mutations in human immunodeficiency virus type 1 gag in the Pumwani sex worker cohort', Journal of Virology, 82, pp. 1980 - 1992, http://dx.doi.org/10.1128/JVI.02742-06

Conference Papers

Maddula M; Cohen JE; Kumarasinghe D; Ballinger ML; Tearle JLE; James KR; Nagrial A; Barnet M; Thavaneswaran S, 2026, 'Risk Factors in Sporadic Early-Onset Colorectal Cancer, Current Evidence and Emerging Insights: A Systematic Review', in Cancers, http://dx.doi.org/10.3390/cancers18101515

Price TJ; Burge M; Chantrill L; Chua YJ; Horvath L; McLachlan S-A; Pavlakis N; Shapiro J; Thavaneswaran S; Tran B; Yip D; Tancock G, 2020, '107P Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study', in Annals of Oncology, Elsevier, pp. s1283, http://dx.doi.org/10.1016/j.annonc.2020.10.127

Shapiro JD; Thavaneswaran S; Underhill C; Robledo KP; Karapetis CS; Day FL; Nott LM; Jefford M, 2017, 'Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.3572

Segelov E; Thavaneswaran S; Waring P; Desai J; Mann K; Elez E; Chantrill L; Pavlakis N; Nott L; Underhill C; Khasraw M; Wasan H; Ciardiello F; Jefford M; Joubert W; Haydon A; Karapetis C; Price T; Wilson K, 2015, 'The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.', in Eur J Cancer, Vienna, pp. S726 - S726, presented at European Cancer Congress, Vienna, 25 September 2015 - 29 September 2015

Conference Presentations

Segelov E; Thavaneswaran S; Waring P; Desai J; Mann K; Elez E; Chantrill L; Pavlakis N; Nott L; Underhill C; Khasraw M; Wasan H; Ciardiello F; Jefford M; Joubert W; Haydon A; Karapetis C; Price T; Wilson K; Shapiro J, 2015, '32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation', http://dx.doi.org/10.1016/s0959-8049(15)30078-2

Conference Abstracts

Gaughran G; Caillet V; Harris SJ; Thavaneswaran S; Ballinger ML; Zong J; Said Q; Bernard-Gauthier V; Kee D; Napier CE; Zaheed M; Papadopoulos L; Yap M; Simes J; Thomas DM, 2026, 'HER2 mutations in advanced NSCLC: Prevalence, mutational context, and clinical outcomes from an Australian clinico-genomic database.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 44, pp. e20673 - e20673, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 29 May 2026 - 02 June 2026, http://dx.doi.org/10.1200/JCO.2026.44.16_suppl.e20673

Yuile A; Satgunaseelan L; Alexander KL; Thavaneswaran S; Sim H-W; Zaman A; Powell J; Meng A; Escher C; Wei JQ; Wei G; Lee M; Buckland ME; Kong BY; Kastelan M; Wong M; Wilson I; Bayly A; Varikatt W; Lwin Z; Rodriguez M; Soh HC; Gill A; Zakarya R; Back MF; Pavlakis N; Chan DL; Lee A; Wheeler HR; Hudson AL, 2025, 'PATH-18. Investigating the role of CDKN2A loss in IDH-mutant gliomas: biological insights beyond tumour grading', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v243 - v244, http://dx.doi.org/10.1093/neuonc/noaf201.0970

Southi N; Sim H-W; Grady J; Satgunaseelan L; Huang M; Kansara M; Yuile A; Zaman A; Lin F; Wheeler H; Hudson A; Ballinger ML; Thomas DM; Thavaneswaran S, 2025, 'PATH-52. Understanding the prevalence ofMTAP andCDKN2A/B deletion in gliomas by next generation sequencing', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v252 - v252, http://dx.doi.org/10.1093/neuonc/noaf201.1004

Thavaneswaran S; Koh E-S; Sim H-W; Ballinger ML; Thomas DM; Barnes EH; Kong B; O’Callaghan C; Pitz M; Hawkins C; Roberge D; Pallimulla S; Ralston L; Yip S; Day BW; Verhaak RGW; Buckland M; Amanuel B; Simes J; De Lourenco RA; Solano NZ; Calder R; Adda L; Ahern E; Cooper A; Dowling A; Harrup R; Kichenadasse G; Lau B; Lynam J; Lwin Z; Wheeler H; Whittle JR; Norrie A; Harrison R; Mason WP; de Robles P; Maddula M; Gan HK, 2025, 'TIP-16. Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v423 - v424, http://dx.doi.org/10.1093/neuonc/noaf201.1676

Thavaneswaran S; Espinoza D; Lin FP; Chinchen S; Kansara M; Ballinger M; Grady J; Grimison P; Millward M; Ladwa R; Joshua AM; Desai J; Simes J; Thomas D, 2025, '973P Phase II trial of Vismodegib in advanced cancers with Hedgehog pathway alterations', in Annals of Oncology, Elsevier, Vol. 36, pp. s637, http://dx.doi.org/10.1016/j.annonc.2025.08.1542

Lin FP; Mersiades A; Lee J; Xu W; Chinchen S; Charakidis M; Thavaneswaran S; Hughes BGM; Underhill CR; Takhar HS; Harrup R; Nagrial A; Millward M; Desai J; Espinoza D; Lee CK; Solomon BJ; Simes J; Pavlakis N; Thomas D, 2024, '623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12', in Annals of Oncology, Elsevier, SPAIN, Barcelona, Vol. 35, pp. s498, presented at Annual Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 13 September 2024 - 17 September 2024, http://dx.doi.org/10.1016/j.annonc.2024.08.690

Lin FPY; Grady JP; Napier CE; Callow M; Thavaneswaran S; Huang ML; Zaheed M; Kansara M; Sebastian L; Ballinger ML; Simes J; Thomas DM, 2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.', in Journal of Clinical Oncology, Vol. 42, pp. 1557 - 1557, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.1557

Kong BY; Lin FP-Y; Espinoza D; Thavaneswaran S; Meniawy T; Desai J; Harrup R; Selva-Nayagam S; Charakidis M; Cuff K; Sebastian L; Lee CK; Chinchen S; Thomas DM; Ballinger ML; Simes J; Goldstein D, 2024, '636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy', in Annals of Oncology, Elsevier, Vol. 35, pp. s505, http://dx.doi.org/10.1016/j.annonc.2024.08.703

Serie D; Pickering C; Rice R; Wong M; Huang H; Kansara M; Thavaneswaran S; Ballinger ML; Sebastian L; Thomas DM; Lindpaintner K, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3073

Serie D; Pickering C; Rice R; Wong M; Huang H; Kansara M; Thavaneswaran S; Ballinger ML; Sebastian L; Thomas DM; Lindpaintner K, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11546 - 11546, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11546

Thavaneswaran S; Ballinger ML; Grady J; Cowley M; Joshua A; Sebastian L; Collignon E; Silvestri A; Kansara M; Pinese M; Sjoquist KM; Hague W; Lee CK; Simes J; Thomas DM, 2019, 'The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. 3136 - 3136, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3136

Thavaneswaran S; Sebastian L; Ballinger M; Cowley M; Grady J; Joshua A; Lee C; Sjoquist K; Hague W; Simes J; Thomas D, 2018, 'The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii147, http://dx.doi.org/10.1093/annonc/mdy279.434

Preprints

Tran M; Chan JC; Huang ML; Kansara M; Grady JP; Napier CE; Thavaneswaran S; Ballinger ML; Thomas DM; Lin FP, 2025, A Robust BERT-Based Deep Learning Model for Automated Cancer Type Extraction from Unstructured Pathology Reports, http://dx.doi.org/10.48550/arxiv.2508.15149

Thavaneswaran S; Lin FP; Kansara M; Grady JP; Espinoza D; Joshua AM; Grimison P; Craft P; Cosman R; Lee C; Harwood K; Chinchen S; Corpuz T; Ballinger M; Sebastian L; Simes J; Thomas D, A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers, http://dx.doi.org/10.1101/2022.06.30.22277092

Thavaneswaran S; Sebastian L; Kansara M; Ballinger M; Espinoza D; Lin F; Lee C; Sjoquist K; Grady J; Cowley M; Joshua A; Qiu M; Oakes S; Simes J; Thomas D, A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program, http://dx.doi.org/10.21203/rs.3.rs-254137/v1

Meng A; Yuile A; Sim H-W; Thavaneswaran S; Noor H; Yeung J; Mehta A; Powell J; Zaman A, A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours, http://dx.doi.org/10.1101/2025.02.03.25321619

Lin FP; Thavaneswaran S; Grady JP; Ballinger M; Kansara M; Oakes SR; Desai J; Lee CK; Simes J; Thomas DM, Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology, http://dx.doi.org/10.1101/2020.12.18.20248521

Other

Cote GM; Aberoumand M; Choy E; Sebastian L; Mazzola E; Grimison P; Merriam P; Ballinger M; Thavaneswaran S; Lin F; Grady JP; Millward M; Brown MP; Harrup R; Espinoza D; Demetri G; Littlefield BA; Simes RJ; George S; Thomas D, 2026, Data from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma, http://dx.doi.org/10.1158/1078-0432.c.8509442

Cote GM; Aberoumand M; Choy E; Sebastian L; Mazzola E; Grimison P; Merriam P; Ballinger M; Thavaneswaran S; Lin F; Grady JP; Millward M; Brown MP; Harrup R; Espinoza D; Demetri G; Littlefield BA; Simes RJ; George S; Thomas D, 2026, Supplementary Tables 1-3 from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma, http://dx.doi.org/10.1158/1078-0432.32530688

Back to profile page